FDA approves first treatment for sexual desire disorder

The U.S. Food and Drug Administration approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Prior to Addyi’s approval, there were no FDA-approved treatments for sexual desire disorders in men or women.

Full Story: fda.gov

You Might Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *